Table 1. Characteristics of the study population according to quartile of HPR.
| Baseline demographics | Patients N = 739 | Quartile of platelet reactivity | P* | |||
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||
| Gender m/f (%) | 77.5/22.5 | 75.5/24.5 | 80.7/19.3 | 81/19 | 72.8/27.2 | 0.081 |
| Age (years) | 69 (61–75) | 67.0 (57–74) | 68.0 (59.0–74.0) | 70.0 (63.0–74.0) | 69.0 (64.5–74.5) | 0.051 |
| Body mass index | 27.4 (25.1–30.5) | 26.1 (24.3–26.1) | 27.1 (25.46–30.1) | 28.4 (25.8–30.75) | 28.3 (26.04–31.77) | 0.001 |
| Adiposity BMI>30 (%) | 24.5 | 18.7 | 25.3 | 32.7 | 36.8 | 0.007 |
| Hypertension (%) | 82.9 | 80.1 | 81.8 | 86.4 | 87.6 | 0.129 |
| Smoking history | 39.0 | 42.4 | 40.8 | 38.9 | 38.1 | 0.536 |
| Hyperlipidemia (%) | 73.9 | 73.7 | 67.4 | 80.4 | 74.0 | 0.969 |
| Diabetes mellitus (%) | 30.9 | 22.6 | 27.1 | 34.2 | 41.0 | 0.001 |
| Serum creatinin mg/dL | 1.0 (0.9–1.2) | 1.1 (0.9–1.2) | 1.1 (0.9–1.3) | 1.0 (0.9–1.28) | 1.1 (0.9–1.4) | 0.021 |
| Left ventricular function (%) | 55.7 (49–65) | 55.7 (50–58) | 60 (49–65) | 60 (49–65) | 54.5 (46–65) | 0.083 |
| Medication | ||||||
| Statins (%) | 88.9 | 87.0 | 90.2 | 91.4 | 86.9 | 0.367 |
| ACE- Inhibitors(%) | 77.4 | 77.6 | 76.8 | 79.3 | 76.0 | 0.615 |
| Angiotensin receptor blockers (%) | 11.6 | 13.7 | 8.5 | 16.5 | 14.9 | 0.514 |
| β-blockers (%) | 91.0 | 93.8 | 89.6 | 90.9 | 89.6 | 0.501 |
| Multivessel disease | 74.1 | 69.7 | 74.7 | 85.2 | 76.9 | 0.424 |
| Bare metal stents/ drug-eluting stents/both | 65.7/24.5/9.7 | 66.7/22.6/10.7 | 61.3/27.5/11.3 | 63.6/27.2/9.3 | 71.6/20.6/7.7 | 0.08/0.20/0.33 |
* for quartile 4 vs. 1–3.